Bank of America Securities issued a research report stating that it expects ALI HEALTH's revenue for fiscal year 2026 to meet expectations. Considering the company's investments in artificial intelligence and innovative drug sales since the second half of the year, the firm has revised its forecast for ALI HEALTH's adjusted net profit for fiscal 2026 down to a year-on-year increase of 20% (previously expected to grow by 35%). The bank has lowered ALI HEALTH's target price from HK$6.56 to HK$6, while reaffirming its "Buy" rating.